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Abstract Ornithine transcarbamylase (OTC) (E.C.
2.1.3.3) is one of the enzymes in the urea cycle, which
involves in a sequence of reactions in the liver cells.
During protein assimilation in our body surplus nitrogen is
made, this open nitrogen is altered into urea and expelled
out of the body by kidneys, in this cycle OTC helps in the
conversion of free toxic nitrogen into urea. Ornithine
transcarbamylase deficiency (OTCD: OMIM#311250) is
triggered by mutation in this OTC gene. To date more than
200 mutations have been noted. Mutation in OTC gene
indicates alteration in enzyme production, which upsets the
ability to carry out the chemical reaction. The computa-
tional analysis was initiated to identify the deleterious
nsSNPs in OTC gene in causing OTCD using five different
computational tools such as SIFT, PolyPhen 2, I-Mutant 3,
SNPs&Go, and PhD-SNP. Studies on the molecular basis
of OTC gene and OTCD have been done partially till date.
Hence, in silico categorization of functional SNPs in OTC
gene can provide valuable insight in near future in the
diagnosis and treatment of OTCD.
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Introduction
Ornithine transcarbamylase (OTC) catalyzes the formation
of citrulline from carbamoyl phosphate and L-ornithine in
the urea cycle, deleterious mutations in the human OTC
gene disrupts the formation and produces clinical hyper-
ammonemia, which can also lead to encephalopathy with
subsequent neurological symptoms or even death. Ornithine
transcarbamylase deficiency (OTCD) is the most common
inborn error of urea cycle showing X-linked inheritance,
which occurs at a predictable frequency of 1 in 14,000
births. Affected individuals show elevated levels of ammo-
nia in their plasma and amplified urinary flow of orotic acid
(Lopes-Marques et al. 2012). Males with OTCD show
neonatal ammonia intoxication with severe or fatal neuro-
logical damage. Those with limited enzymatic OTCD may
perhaps have a normal life span, but are at the peak intended
for stress-induced hyperammonemic emergencies and
incremental neurological damage. Females are carriers who
might be asymptomatic, but often show some amount of
protein intolerance (Maddalena et al. 1988). The human
OTC gene is found on the short arm of the X chromosome
with its cytogenetic location being Xp21.1. The size of the
gene is 73 kb with an open reading frame of 1,062 nucle-
otides and holds 10 exons interjected by 9 introns of highly
variable size. The OTC gene is expressed entirely in the liver
and small intestinal mucosa. It translates a precursor OTC
protein containing 354 amino acids and the amino end
contains a spearhead sequence of 32 amino acids, which is
cleaved in two steps upon integration into the mitochondrial
matrix (Ogino et al. 2007). A polymorphism is a germline
variation in the nucleotide base of the DNA molecule. As a
rule of thumb inheritable variation is termed, a polymor-
phism if it is present at an allele frequency greater than 1 %
in the general population, otherwise, at lower frequencies, it
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is considered as germline mutation (Strachan and Read
1996). Genetic polymorphisms are present throughout the
genome of human. The most common type of polymorphism
is single nucleotide polymorphism (SNP) that can occur in
the frequency of about 1 out of every 300 nucleotide base
pairs, and there are probably more than 10 million SNPs in
the human population (The international HapMap and
Consortium 2006). Polymorphisms can occur in both coding
and non-coding region of the genes and may sometimes,
particularly those within exons, have an impact on the
structure and function of the protein coded by a particular
gene, especially in those cases when the polymorphism leads
to an amino acid substitution in evolutionarily conserved
functional region of the protein.
A polymorphism that takes to an amino acid substitution
and is present within an active site of an enzyme, at a
substrate-binding site, a DNA-binding site or in other areas
of the protein domains may affect the function of the
encoded protein. This is particularly correct if the substi-
tuted amino acid has a different 3D structure or electrical
charge than the wild-type amino acid, as this will alter the
conformation or affinity of the enzyme, and make it non-
functional, or more or less efficient than the wild-type
protein (AliOsman et al. 1997; Hadi et al. 2000; Matullo
et al. 2001; Pemble et al. 1994).
The loss of stability of proteins is one of the foremost
causes of disease. As the proteins are only marginally sta-
ble, even small effects on stability alter the thermodynamic
equilibrium to make the folded state unstable. Mutational
data show that mutations often, if not in the majority of
cases, cause significant changes to protein stability which
are often on the order of magnitude of the absolute stability
of the protein (Guerois et al. 2002). Lowered stability leads
to a reduction in a protein’s effective concentration, which
in turn causes deficiencies in its ability to perform its bio-
chemical function (Pakula et al. 1986).
Mutations in this OTC gene are the main reason for
OTCD. Deleterious non-synonymous single nucleotide
polymorphism (nsSNP) analysis for the OTC gene has not
been projected computationally until now, while they are
the center for new investigators. Therefore, in this work,
the computational methods namely SIFT, PolyPhen 2,
I-Mutant 3, SNPs&Go, and PhD-SNP were used to identify
the deleterious nsSNPs that are expected to be affecting the
function and structure of the OTC protein.
Materials and methods
Dataset used for SNP annotation
Human OTC gene information data were collected from
Online Mendelian Inheritance in Man (OMIM) (Amberger
et al. 2009) and Entrez Gene on National Centre for Bio-
logical Information (NCBI). The SNP information of CBS
was retrieved from the NCBI dbSNP (Sherry et al. 2001),
and SWISS-Prot databases (Amos and Rolf 1996). Protein
3D structure was obtained from protein data bank (PDB)
(Berman et al. 2000).
Sorting intolerant from tolerant (SIFT)
Sequence homology-based tool SIFT predicts the functional
importance of amino acid substitution based on the align-
ment of highly similar orthologous and/or paralogous pro-
tein sequences. SIFT scores were designated as intolerant
(0.00–0.05), potentially intolerant (0.051–0.10), borderline
(0.101–0.20), or tolerant (0.201–1.00) (Kumar et al. 2009).
PolyPhen 2
PolyPhen2 (Polymorphism Phenotyping) predicts the func-
tional effect of amino acid changes by considering evolu-
tionary conservation, the physico-chemical differences, and
the proximity of the substitution to predicted functional
domains and/or structural features. A mutation is classified
as ‘‘probably damaging’’ if the probabilistic score is above
0.85–1, mutation is classified as ‘‘possibly damaging’’ if the
probabilistic score is above 0.15–0.84, and the remaining
mutations are classified as benign (Adzhubei et al. 2010).
I-Mutant 3
SVM-based method I-Mutant 3 predicts the protein sta-
bility changes upon a single point mutation. It provides free
energy change (DDG), which is calculated from the
unfolding Gibbs free energy change of the mutated protein
minus the unfolding free energy value of the native protein
(Kcal/mol). It classifies the predictions in three classes: If
DDG is \-0.5 = large decrease of stability, If DDG is
between -0.5 and 0.5 = neutral stability and If DDG is
[0.5 = large increase of stability (Capriotti et al. 2005).
SNPs&GO
It is a method based on SVMs that predict disease-associated
mutations from protein sequence, evolutionary information
and functions as encoded in the gene ontology terms. More-
over, it is a server for the predicting single point mutations,
which cause disease in humans (Calabrese et al. 2009).
PhD-SNP
PhD-SNP uses SVM-Sequence method and SVM profile to
classify the mutation into disease related and neutral poly-
morphisms. It predicts if the given nsSNP has pathological
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effect based on the local sequence environment of the
mutation. It uses the most accurate mode that enables both
sequence and evolutionary profiles (Capriotti et al. 2006).
Structural analysis
To evaluate the structural stability of native and mutant,
protein structure analysis was performed. We used the web
resource dbSNP to identify the protein coded by OTC. We
also confirmed the mutation positions and the mutation res-
idues from this server. These mutation residues and their
corresponding positions were in complete agreement with
the results obtained from the in silico prediction methods
SIFT, PolyPhen 2, I-Mutant 3, SNPs&GO and PhD-SNP.
The mutation was performed using SWISS-PDB viewer
(Guex and Peitsch 1997), and energy minimization for 3D
structures was performed by NOMAD-Ref server (Lindahl
et al. 2006). This server uses Gromacs as default force field
for energy minimization based on the methods of steepest
descent, conjugate gradient and L-BFGS methods. Conju-
gate gradient method was used for optimizing the 3D
structures. Deviation between the two structures was eval-
uated by their Root Mean Square Deviation (RMSD) values.
Results
A total of about 195 SNPs were collected and their dele-
terious natures were analyzed by various computational
methods.
Analysis of deleterious SNPs using evolutionary-based
prediction methods
SIFT algorithm calculates whether an amino acid replace-
ment may have an impact on protein function by aligning
similar proteins and calculating a score which tells the evo-
lutionary conservation status of the amino acid of our
interest. SIFT scores were obtained for 195 SNPs. SIFT
scores were classified as intolerant (0.00–0.05), potentially
intolerant (0.051–0.10), borderline (0.101–0.20), and toler-
ant (0.201–1.00). Approximately 115 (58.97 %) of the SNPs
exhibit SIFT scores of 0.0. Another 45 (23 %) of the variants
have scores between 0.01 and 0.05. Thus, 82 % of the SNPs
are classified as ‘‘intolerant’’ by SIFT. The remaining SNPs
were found to be ‘‘tolerant’’. SIFT gave a prominent result
with an 82 % of predictions to be deleterious.
Analysis of deleterious SNPs using structure-based
prediction methods
The influences of nsSNPs in protein function were tested
using structure-based predictors by applying it to three
different methods. The structural levels of changes of 195
nsSNPs were determined by PolyPhen 2. To provide an
outline of the distribution of PolyPhen 2 scores, the scores
are distributed into three groups. PolyPhen 2 scores falling
between 0.85 and 1 are expected to be ‘‘probably damag-
ing’’ to protein structure and function. 157 (80 %) of the
nsSNPs were found to have scores in the above-mentioned
category. An additional 19 (9.7 %) of the variants exhib-
ited PolyPhen 2 scores of 0.2–0.84, indicative of variants
that are ‘‘possibly damaging’’ to protein function, and the
remaining 17 (8.7 %) nsSNPs that scored less than 0.02
were designated as ‘‘benign’’. SNPs&GO makes use of
sequence and evolutionary information to predict whether a
mutation is disease related or not by developing the protein
functional annotation. The protein sequences with corre-
sponding UniProt accession numbers were submitted along
with their corresponding mutational position, wild-type and
mutant-type residue as input to the server. 98 % of the
nsSNPs were designated as ‘‘disease’’. These mutants are
found to be disease causing. PhD-SNP predicts the given
nsSNPs have pathological effects based on the local
sequence environment of the mutation. It classifies the
SNPs into disease or neutral based on the most accurate
mode that uses both sequence and evolutionary profiles. It
showed 64 % of nsSNPs were likely to cause disease on
mutation.
Prediction of stability changes
Mutated proteins involved in diseases show a stability
change. Predicting the protein stability upon mutation is
necessary for understanding structure function relationship
of protein. Generally, the stability of a protein is represented
by the change in the Gibbs free energy upon folding (DG),
where an increasingly negative number represents greater
stability. Single amino acid substitution in a protein
sequence can result in a significant change in the protein’s
stability (DDG), where a positive DDG represents a desta-
bilizing mutation and a negative value represents a stabi-
lizing mutation. All the 195 nsSNPs submitted to pathogenic
prediction tools were also subjected to protein stability
analysis by I-Mutant 3.0. It gave an estimation of 107
nsSNPs (54 %) caused decreased stability, 48 SNPs (24 %)
were neutral to the mutation, and 39 SNPs (20 %) increased
the stability of protein after mutation. Out of 195 nsSNPs, 92
nsSNPs (47 %) were predicted to be positive by SIFT,
PolyPhen 2, I-Mutant 3, SNPs&Go, and PhD-SNP (Table 1).
Structural analysis
According to the computational prediction in OTC gene,
structural analysis was performed for the five highly del-
eterious variants by modeling mutant structures using
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Table 1 List of nsSNPs in OTC found to be deleterious/neutral by computational methods
S. no. rs IDs Variants SIFT PolyPhen 2 I-Mutant 3 SNPs&GO PhD-SNP
1 rs72552295 M1T 0.01 0.895 -0.28 Disease Neutral
2 rs72552296 M1I 0.03 0.465 0.69 Disease Neutral
3 rs67752076 M1V 0.14 0.064 0.61 Disease Neutral
4 rs137853257 R10P NA NA –1.12 NA Neutral
5 rs148660170 R23Q 0.15 0.139 –0.97 Disease Neutral
6 rs68031618 R26Q 0.59 0.002 –0.84 Disease Neutral
7 rs199858968 G28E 0.06 0.999 –0.82 Disease Neutral
8 rs72554306 G39C 0.01 1 –2.15 Disease Neutral
9 rs72554307 R40C 0 1 1.16 Disease Disease
10 rs72554308 R40H 0.03 0.54 –0.28 Disease Neutral
11 rs74518351 D41G 0.31 0.103 –2.91 Disease Neutral
12 rs72554309 L43F 0.01 1 –1.08 Disease Disease
13 rs72554310 T44I 0.01 1 –2.64 Disease Neutral
14 rs72554311 L45V 0.01 0.967 –0.7 Disease Neutral
15 rs72554312 L45P 0 1 –1.26 Disease Disease
16 rs1800321 K46R 0.49 0.187 –1.02 Disease Disease
17 rs67939655 N47T 0.01 0.07 –0.66 Disease Disease
18 rs72554315 F48S 0.01 1 –0.12 Disease Disease
19 rs72554316 T49P 0 0.922 –1.82 Disease Disease
20 rs201802621 G50A 1 0.02 –0.01 Disease Neutral
21 rs72554317 E52G 0 1 –2.37 Disease Disease
22 rs72554318 E52D 0.01 1 –1.61 Disease Disease
23 rs66521141 E52K 0 1 –1.69 Disease Disease
24 rs66677059 I53T 0 1 –2.68 Disease Disease
25 rs72554319 Y55D 0.23 0.919 –0.42 Disease Neutral
26 rs72554320 M56T 0 0.197 –0.34 Disease Neutral
27 rs72554321 L57Q 0 1 –0.42 Disease Disease
28 rs72554323 S60L 0 1 –1.77 Disease Disease
29 rs72554324 L63P 0.01 1 –0.99 Disease Disease
30 rs72554325 I67R 0.22 1 –1.61 Disease Neutral
31 rs72554328 L76S 0.41 0.994 –0.08 Disease Disease
32 rs72554329 L77F 0 0.998 0.05 Disease Disease
33 rs72554331 G79E 0 1 –1.51 Disease Disease
34 rs72554332 K80E 0.03 0.468 –1.6 Disease Disease
35 rs72554333 K80 N 0 0.997 –2.25 Disease Neutral
36 rs72554336 G83R 0 0.923 –1.04 Disease Disease
37 rs72554337 G83D 0 0.824 –1.85 Disease Disease
38 rs72554338 E87K 0 0.96 –1.56 Disease Disease
39 rs72554339 K88N 0 1 –2.09 Disease Neutral
40 rs72554340 S90G 0 1 –1.65 Disease Disease
41 rs72554341 S90N 0 1 –0.83 Disease Disease
42 rs72554342 S90R 0 1 –2.7 Disease Neutral
43 rs67418243 R92G 0 0.979 –0.37 Disease Neutral
44 rs66550389 R92Q 0 1 –0.55 Disease Disease
45 rs72554344 T93A 0 0.966 –1.39 Disease Disease
46 rs72554345 R94T 0 1 –0.6 Disease Neutral
47 rs72554346 L95S 0 0.283 –2.74 Disease Disease
48 rs184053962 S96R 0 1 –0.86 Disease Disease
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Table 1 continued
S. no. rs IDs Variants SIFT PolyPhen 2 I-Mutant 3 SNPs&GO PhD-SNP
49 rs72554347 E98K 0 1 0.85 Disease Neutral
50 rs72554349 G100D 0 1 0.19 Disease Disease
51 rs1133135 F101L 0.3 0.208 0.61 Disease Neutral
52 rs72554350 A102E 0.29 0.989 1.09 Disease Neutral
53 rs72554351 G105V 0 1 0.14 Disease Disease
54 rs72554352 G106R 0 1 –2.08 Disease Disease
55 rs67651903 G106E 0 1 –1.11 Disease Disease
56 rs1800324 L111P 0 1 –0.47 Disease Disease
57 rs66539573 H117R 0.02 0.993 –1.43 Disease Disease
58 rs72554356 T125M 0.21 0.688 –0.84 Disease Neutral
59 rs72554358 D126G 0 1 –0.68 Disease Disease
60 rs140046498 R129C 0 0.9999 –1.87 Disease Disease
61 rs66656800 R129H 0.02 1 –2.46 Disease Disease
62 rs72556252 L131S 0 1 –2.09 Disease Disease
63 rs72556253 S132P 0 1 0.95 Disease Disease
64 rs72556254 S132F 0 1 1.37 Disease Disease
65 rs72556256 A135E 0.09 0.122 0.53 Disease Disease
66 rs72556257 D136V 0 0.996 0.86 Disease Disease
67 rs72556258 A137T 0.04 0.761 0.19 Disease Neutral
68 rs72556259 L139S 0 1 –0.06 Disease Neutral
69 rs72556260 A140P 0.04 1 –0.46 Disease Disease
70 rs68026851 R141Q 0 1 –0.27 Disease Disease
71 rs67960011 R141G 0 1 –2.51 Disease Disease
72 rs72556261 V142E 0 1 0.55 Disease Disease
73 rs67016166 L148S 0 1 0.1 Disease Neutral
74 rs66741318 L148F 0 1 0.84 Disease Disease
75 rs72556265 L151R 0 1 –0.21 Disease Neutral
76 rs72556266 A152V 0.02 0.791 1.19 Disease Neutral
77 rs72556268 A155E 0 0.999 –0.24 Disease Neutral
78 rs67890094 A155P 0.01 0.999 –1.22 Disease Disease
79 rs72556269 I159T 0 0.99 –3.21 Disease Disease
80 rs67954347 I160N 0 0.996 –0.25 Disease Disease
81 rs72558497 N161K 0 1 –1.25 Disease Disease
82 rs72556270 N161D 0 1 0.44 Disease Disease
83 rs72556271 N161S 0.03 0.998 0.17 Disease Neutral
84 rs72556272 G162E 0 1 –1.58 Disease Neutral
85 rs66626662 G162R 0 1 –0.57 Disease Neutral
86 rs72556273 S164P 0 1 –0.34 Disease Disease
87 rs72556275 D165Y 0 1 –0.73 Disease Neutral
88 rs72556276 H168Q 0 1 –1.47 Disease Disease
89 rs72556277 P169A 0 1 –0.9 Disease Disease
90 rs72556278 P169L 0 1 –0.6 Disease Disease
91 rs72556279 I172F 0.01 1 –0.91 Disease Disease
92 rs72556280 I172M 0 0.964 –0.5 Disease Neutral
93 rs72556281 A174P 0 1 –1.52 Disease Disease
94 rs68033093 D175G 0.01 1 –3.78 Disease Disease
95 rs72556282 Y176H 0 0.999 –1.39 Disease Disease
96 rs72556283 Y176C 0 1 –1.39 Disease Disease
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Table 1 continued
S. no. rs IDs Variants SIFT PolyPhen 2 I-Mutant 3 SNPs&GO PhD-SNP
97 rs148961194 L177F 0.02 1 –0.13 Disease Neutral
98 rs72556284 T178M 0 1 –0.51 Disease Disease
99 rs72556286 L179P 0 1 –0.63 Disease Disease
100 rs72556290 E181G 0 0.793 –0.62 Disease Disease
101 rs143746493 H182Q 0.14 1 –1.93 Disease Neutral
102 rs72556291 H182L 0.27 1 –1.06 Disease Neutral
103 rs72556292 Y183D 0.04 1 –1.91 Disease Disease
104 rs72556294 G188R 0 1 –2.08 Disease Disease
105 rs72556295 G188V 0 1 –0.91 Disease Disease
106 rs72556296 L191F 0.13 0.202 –0.08 Disease Disease
107 rs72556297 L191R 0 0.998 –0.03 Disease Disease
108 rs72556298 S192R 0 0.999 –0.57 Disease Disease
109 rs67284661 W193R 0 1 –0.91 Disease Neutral
110 rs67294955 G195R 0 1 –1.97 Disease Disease
111 rs72556300 D196V 0 1 1.37 Disease Disease
112 rs66642398 D196N 0 1 –0.09 Disease Disease
113 rs72556301 G197R 0 1 –0.09 Disease Disease
114 rs72556302 G197E 0 1 0.26 Disease Disease
115 rs72558403 N198I 0 1 0.26 Disease Disease
116 rs72558404 N198K 0 1 –0.84 Disease Disease
117 rs72558405 N199D 0 1 –0.97 Disease Disease
118 rs72558406 N199S 0 1 –0.91 Disease Disease
119 rs72558407 L201P 0.01 1 –0.31 Disease Disease
120 rs72558408 H202Y 0.03 1 –2.74 Disease Neutral
121 rs72558409 H202P 0 0.998 –2.84 Disease Disease
122 rs72558410 S203C 0 1 –3.27 Disease Disease
123 rs72558411 M205V 0.03 0.904 –0.64 Disease Neutral
124 rs72558412 M206R 0.03 0.998 –2.5 Disease Neutral
125 rs72558413 M206I 0.13 0.069 –0.95 Disease Neutral
126 rs72558414 S207N 0.06 0.805 –0.31 Disease Disease
127 rs72558415 S207R 0.01 1 0.42 Disease Neutral
128 rs72558416 A208T 0.08 1 –0.05 Disease Neutral
129 rs72558417 A209V 0.04 1 1.21 Disease Neutral
130 rs72558418 K210Q 0.03 0.897 0.57 Disease Neutral
131 rs72558419 M213L 0.17 0.721 –0.67 Disease Neutral
132 rs72558420 H214Y 0.02 0.98 0.4 Disease Neutral
133 rs72558421 L215F 0.14 0.994 –0.41 Disease Disease
134 rs72558423 Q216E 0.97 0.663 –1.03 Disease Disease
135 rs72558424 A217E 0 0.994 –1.02 Disease Disease
136 rs72558425 P220A 0 1 –1.05 Disease Disease
137 rs72558426 P220L 0 1 –1.15 Disease Disease
138 rs72558428 P225T 0.27 0.954 –0.29 Disease Neutral
139 rs67120076 P225R 0.03 0.975 0.12 Disease Disease
140 rs72558429 A233V 0 0.998 –1.49 Disease Neutral
141 rs4385598 Q235Q 0.83 NA NA NA NA
142 rs67283833 E239G 0.16 0.85 –0.47 Disease Disease
143 rs72558435 T242I 0.05 1 –0.23 Disease Disease
144 rs72558436 L244Q 0 0.854 –0.11 Disease Disease
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Table 1 continued
S. no. rs IDs Variants SIFT PolyPhen 2 I-Mutant 3 SNPs&GO PhD-SNP
145 rs72558437 T247K 0.03 0.974 –0.55 Disease Disease
146 rs67330615 A253T 0 1 –2.18 Disease Disease
147 rs72558440 H255P 0.02 0.017 –0.9 Disease Disease
148 rs142592280 N258S 0 0.688 –1.72 Disease Disease
149 rs72558441 L260S 0 1 0.24 Disease Disease
150 rs67333670 T262K 0 1 –0.62 Disease Disease
151 rs72558442 D263N 0 1 0.33 Disease Neutral
152 rs72558443 D263G 0 1 –1.23 Disease Disease
153 rs72558444 T264A 0.01 0.998 –2.53 Disease Disease
154 rs67156896 T264N 0.03 0.902 –1.76 Disease Disease
155 rs72558445 W265R 0 0.996 –0.87 Disease Disease
156 rs72558446 W265L 0 1 –0.26 Disease Disease
157 rs72558448 S267R 0 1 –0.51 Disease Disease
158 rs72558449 M268T 0 1 –1.98 Disease Disease
159 rs72558450 G269E 0 1 –1.43 Disease Disease
160 rs72558451 Q270E 0.01 0.923 –1.13 Disease Disease
161 rs1800328 Q270P 0 0.284 –2.14 Disease Disease
162 VAR_004927 Q270R 0 0.977 –1.14 Disease Disease
163 rs72558454 R277W 0 1 –0.46 Disease Disease
164 rs66724222 R277Q 0 1 –0.35 Disease Disease
165 rs72558461 W298S 0.05 0.987 –0.96 Disease Neutral
166 rs72558462 L301F 0.01 0.997 0.16 Disease Disease
167 rs72558463 H302Y 0 1 1.2 Disease Disease
168 rs67993095 H302R 0 1 –0.1 Disease Neutral
169 rs67870244 H302K 0 1 0.21 Disease Neutral
170 rs72558464 C303Y 0 1 0.74 Disease Disease
171 rs67468335 C303R 0 1 0.28 Disease Disease
172 rs72558465 L304F 0 0.999 1.14 Disease Disease
173 rs67501347 P305H 0 1 –2.28 Disease Disease
174 rs72558467 E310G 0 1 –3.46 Disease Disease
175 rs72558468 V311M 0 1 –0.27 Disease Neutral
176 rs137899554 E314A 0.11 0.003 –1.44 Disease Neutral
177 rs72558470 V315F 0 0.999 –0.97 Disease Disease
178 rs67414444 V315D 0 1 –3.9 Disease Disease
179 rs72558471 F316S 0 0.999 –0.05 Disease Neutral
180 rs72558472 S318F 0.04 0.555 –0.51 Disease Disease
181 rs72558474 R320L 0.01 0.948 –1.64 Disease Disease
182 rs72558476 E326K 0 1 –0.52 Disease Disease
183 rs72558478 R330G 0 1 –2.29 Disease Neutral
184 rs72558480 W332R 0.03 1 –0.84 Disease Disease
185 rs72558486 A336S 0.16 0.791 0.41 Disease Disease
186 rs72558487 V337L 0.32 0.007 1.53 Disease Neutral
187 rs199568993 M338L 0.56 0.012 1.21 Disease Neutral
188 rs72558488 V339L 0.3 0.001 1.1 Disease Neutral
189 rs72558489 S340P 0.09 0.996 0.77 Disease Neutral
190 rs72558490 L341P 0 1 –0.85 Disease Disease
191 rs72558491 T343K 0.92 0.101 –0.48 Disease Neutral
192 rs72558492 Y345C 0.01 0.999 –1.92 Disease Neutral
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native X-ray crystallographic structure (PDB ID: 1OTH).
An energy minimization study gives the information about
the protein structure stability. We checked the total energy
for native- and mutant-type structures. In OTC gene,
mutation occurred for the native protein in ‘A’ chain of
protein structure at position D126G, R141Q, A174P,
T178M and G195R. It can be seen that the total energy
value and RMSD of native-type and mutant-modeled
structures (D126G, A174P, and G195R) were found to be
higher (Table 2).
The mutations for 1OTH at their corresponding positions
were performed by SWISS-PDB viewer independently to
achieve modeled structures. Then, energy minimizations
were performed by NOMAD-Ref server for the native-type
protein 1OTH and the mutant-type structures. The RMSD
values between the native type (1OTH) and the mutant
D126G is 2.01 A˚, between the native type and the mutant
A174P is 2.82 A˚, and between the native type and the mutant
G195R is 2.82 A˚, respectively. The deviation between the
two structures is evaluated by their RMSD values, which
could affect the stability and functional activity. The RMSD
values of all the mutant structures were all alike. Higher the
RMSD value more will be the deviation between native- and
mutant-type structures and which in turn changes their
functional activity. Superimposition of native with the
mutant protein D126G, R141Q, A174P, T178M and G195R
of OTC gene is shown in (Fig. 1a–e). The total energy for the
native and mutant type structures were found to be
-25480.939, -24899.660, -25068.101, -24881.020,
-24969.936 and -24608.215 kcal/mol respectively
(Table 3).
Analysis of local environment changes
Within the range of 4 A˚ from the mutational point, sur-
rounding amino acid changes were analyzed for native and
mutant protein structures. It was observed through PyMOL
(DeLano 2002). Figure 2 shows the substitution of hydro-
philic residue aspartic acid to hydrophobic residue glycine
at position 126, which leads to hydrophobic change at the
core of the protein that could result in the destabilization of
the gamma turns. The drift in hydrophilic to hydrophobic
property can result in the gain of one amino acid LEU 131
in mutant structure.
Figure 3 illustrates the substitution of the hydrophilic
residue arginine with another hydrophilic residue gluta-
mine at position 141, which leads to structural modifi-
cation at the core region of the protein due to the size of
the substituted amino acid, and that could result in
affecting the strand portion. The changes in the amino
acid size results in loss of four amino acids ARG330,
HIS268, LEU139, and THR93 in mutant R141Q struc-
ture. Substitution of hydrophobic residue alanine with
another hydrophobic residue proline and changes in the
surrounding amino acids are shown in Fig. 4. Since the
size of the substituted amino acid has the same size of
the native residue, these changes were not affected the
surrounding amino acids in A174 P-mutant structure.
Figure 5 shows the substitution of non-polar hydrophobic
amino acid glycine with polar hydrophilic larger amino
acid arginine at position 195 of OTC protein. Substitution
of small amino acid glycine with large amino acid
arginine leads to gain of seven SER267, THR264,
ILE200, ASP263, TRP265, ASN198, and LEU252 amino
acids in the surrounding region of mutant structure. This
change may affect the gamma turn of the native protein.
Substitution of polar hydrophobic amino acid threonine at
position 178 with non-polar hydrophobic amino acid
methionine is shown in Fig. 6. This substitution leads to
gain of one amino acid in the mutant structure and this
change may affect the helix region of the native OTC
protein.
Table 1 continued
S. no. rs IDs Variants SIFT PolyPhen 2 I-Mutant 3 SNPs&GO PhD-SNP
193 rs66469337 Y345H 0.23 0.042 –2.64 Disease Neutral
194 rs72558493 P347T 0.02 0.997 –0.62 Disease Neutral
195 rs72558495 F354C 0 0.791 –0.22 Disease Neutral
rs IDs highlighted in bold were found to be deleterious by SIFT, PolyPhen 2, I-Mutant 3, SNPs&GO and PhD-SNP
Table 2 Summary of deleterious nsSNPs in the coding region of OTC gene
RS IDS Amino acid position SIFT PolyPhen 2 I-Mutant 3 SNPs&GO PHD-SNP
rs72554358 D126G 0 1 –0.68 Disease Disease
rs68026851 R141Q 0 1 –0.27 Disease Disease
rs72556281 A174P 0 1 –1.52 Disease Disease
rs72556284 T178M 0 1 –0.51 Disease Disease
rs67294955 G195R 0 1 –1.97 Disease Disease
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Secondary structural changes analysis
The number of secondary structure elements such as Beta
sheets, Beta–Alpha Beta, Strands, Helices, Helix–Helix
Interacs, Beta Turns, and Gamma Turns was calculated for
both the native and mutant models (Table 4). It has to note
that the observed numbers of secondary structural elements
are equal in both native and mutant models except the
Helix–Helix Interacs and Beta Turns. There was a slight
decrease in the number of beta turns in mutant models
D126G, R141Q, A174P, T178M, and G195R as 15, 12, 15,
12, and 15, respectively. The number of beta turn was
increased by one in three mutant models R141Q, A174P,
and T178M. These secondary structural element changes
lead to changes in the physiochemical properties of the
mutant structure (Table 5) and it may affect the protein
stability and conformation.
Discussion
Last decade has witnessed the accelerated expansion of
information regarding the genomic variants especially
SNPs in public databases as a result of improved second
generation sequencing technologies. After polymorphism
information has become abundant in public databases,
many groups started to develop in silico tools that would
computationally calculate the properties of these poly-
morphisms, particularly trying to extrapolate the effect of
Fig. 1 Superimposition of native and mutant modeled structures
(cartoon shape) of OTC protein. a Superimposed structure of native
amino acid aspartic acid (green) with mutant amino acid glycine (red)
at position 126. b Superimposed structure of native amino acid
arginine (green) with mutant amino acid glutamine (red) at position
141. c Superimposed structure of native amino acid alanine (green)
with mutant amino acid proline (red) at position 174. d Superimposed
structure of native amino acid threonine (green) with mutant amino
acid methionine (red) at position 178. e Superimposed structure of
native amino acid glycine (green) with mutant amino acid arginine
(red) at position 195










Native 0.00 –25,480.939 5
D126G 2.01 –24,899.660 3
R141Q 1.84 –25,068.101 4
A174P 2.82 –24,881.020 4
T178M 1.94 –24,969.936 3
G195R 2.82 –24,608.215 3
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polymorphism that has on the phenotype. If dataset on the
phenotypic impact is unknown (owing to the insufficiency
of clinical data or experimental) or not specified, most of
the tools set out to identify whether a polymorphism is
detrimental or not. Anyhow, in order for the identification,
to be accurate, information had to be accumulated on the
features distinguishing neutral from deleterious polymor-
phisms; many tools and algorithms that support large-scale
analyses of SNPs (In particular nsSNPs). Various
computational methods have been developed for predicting
the significant missense mutations based on sequence and
structural methods. With respect to the information utilized
by the prediction, existing methods can be roughly grouped
into three categories: ‘sequence-based’, ‘structure-based’
and ‘sequence and structure-based’, respectively.
Sequence-based methods can be subcategorized into
sequence homology-based and single sequence-based
methods. Sequence homology-based method methods in
Fig. 2 Surrounding amino acid changes in native OTC and mutant D126G structures
Fig. 3 Surrounding amino acid changes in native OTC and mutant R141Q structures
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this category calculate the probability of the substitutions
based on multiple sequence alignments (Ferrer-Costa et al.
2004; Shen and Vihinen 2004). Sequence homology-based
tools are derived based on the premise that essential amino
acids are conserved in the protein family. Hence, changes
at well-conserved positions tend to be predicted as dele-
terious. This probabilistic method provides information
about conserved sites in evolution that are often structur-
ally or functionally important and distinguishes between
missense mutations involved in disease and those that are
functionally neutral. For sequence homology-based meth-
ods, the prediction accuracy depends heavily on the
availability of enough homologs in protein databases.
Saunders and Baker (2002) showed that the prediction
accuracy decreased significantly when fewer than 5–10
homologous sequences are available. An ideal alignment
should be composed of a diverse set of orthologous
sequences rather than paralogs. Structure-based methods
make predictions based on structural information, espe-
cially that of amino acid side-chain conformation, over
Fig. 4 Surrounding amino acid changes in native OTC and mutant A174P structures
Fig. 5 Surrounding amino acid changes in native OTC and mutant G195R structures
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packing and residue–residue contacts (Gonzalez Diaz et al.
2005). The substitution of a wild-type residue may lead to
altered chemical and physical properties, thus causing
structural arrangements. The third method category com-
bines information on the sequence features, the structural
parameters and contacts to characterize the substitution.
The incorporation of structural data greatly improves the
quality of the multiple sequence alignment and the accu-
racy of prediction. This is well illustrated by PolyPhen
(Ramensky et al. 2002), a multiple sequence alignment
server that aligns sequences using structural information. It
may outperform the single sequence-based program SIFT
(Ng and Henikoff 2003) in predicting the effect of amino
acid mutations. In addition to PolyPhen, diverse Web-
based programs are used to predict mutation effects based
on homology and three-dimensional structural models, e.g.,
PROMALS3D (Pei et al. 2008), 3Dcoffee (O’Sullivan
et al. 2004), Expresso (Armougom et al. 2006), CLU-
STALW (Thompson et al. 1994), MUSCLE (Edgar 2004),
PRALINE (Simossis and Heringa 2005), SPEM (Zhou and
Zhou 2005). The user only needs to provide sequences, the
server runs BLAST to identify close homologues of the
sequences within the PDB database.
Study of the molecular basis of diseases using experi-
mental methods is often labor intensive, and time con-
suming, especially in cases where there are several
missense mutations causing the disease. These studies are
difficult to mount on a scale that may be required for
characterizing the genetic variants and at times these
results might not always reflect the in vivo genotype
function in humans. In contrast, precise and useful infor-
mation about the effects of mutations on protein structure
and function can be readily obtained by in silico methods.
Our study gains significance by predicting the possible
deleterious SNPs in OTC gene, so that the number of SNPs
screened for association with diseases can be reduced to
those that are most likely to alter gene function. All the
above methods defined here follow a similar technique in
which each SNP is first labeled with the properties related
to damage it may cause on protein structure and function.
Fig. 6 Surrounding amino acid changes in native OTC and mutant T178M structures
Table 4 Secondary structural elements in native and mutant structure of OTC gene
S. no. Variant Sheet Beta-alpha-beta units Strands Helices Helix–Helix interacs Beta turns Gamma turns
1 Native 2 5 9 15 16 23 3
2 D126G 2 5 9 15 15 23 3
3 R141Q 2 5 9 15 12 24 3
4 A174P 2 5 9 15 15 24 3
5 T178M 2 5 9 15 12 24 3
6 G195R 2 5 9 15 15 23 3
Change in the secondary structure elements are highlighted in bold
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The resulting feature vector is then used to determine
whether a single residue substitution has any effect on
protein function or not. Considering SNPs based on the
amino acid properties are generally reflected to be an
important phenomenon in defining the protein folding,
stability, and its function. The results from this paper sig-
nify the impact of mutations in OTC gene in causing
OTCD. Further, studies possibly will help in uncluttered
nature of OTCD. It is hoped that the results obtained from
this study would pave the way by providing useful infor-
mation to the researchers, and can play an important role in
bridging the gap between biologists and bioinformaticians.
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